×

Modulation of eIF4E-BP2 expression

  • US 8,067,386 B2
  • Filed: 11/19/2008
  • Issued: 11/29/2011
  • Est. Priority Date: 01/22/2004
  • Status: Expired due to Fees
First Claim
Patent Images

1. A pharmaceutical composition comprising a modified antisense compound 13 to 80 nucleobases in length targeted to a nucleic acid molecule encoding eIF4E-BP2, wherein said compound has at least an 8 nucleobase portion 100% complementary within nucleotides 1393-1599 of SEQ ID NO:

  • 4 encoding eIF4E-BP2, wherein said compound has at least 95% complementarity with SEQ ID NO;

    4 and inhibits the expression of eIF4E-BP2 mRNA; and

    a pharmaceutically acceptable carrier or diluent.

View all claims
  • 0 Assignments
Timeline View
Assignment View
    ×
    ×